About this trial
All patients will be completed collection of demographic data, clinical data, and be observed for inflammatory organ damage, oxygenation index or SpO2/ FIO2, WBC, NEU, interleukin-1β, interleukin-6, interleukin-8 (IL-1β/6/8), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), procalcitonin (PCT), myoglobin (Myo), creatine kinase-MB (CK-MB), high-sensitivity cardiac troponin T (hs-cTnT), neutrophil elastase (NE), myeloperoxidase (MPO), APACHE II score, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, Murray lung injury score, serum creatinine, eGFR, mechanical ventilation time, ICU length of stay, drug-related gastrointestinal reactions, and 30-day and 90-day all-cause mortality, among other indicators.
Eligibility criteria
Qualifiers
Aged between 50 and 80 years, male or female;
Patients undergoing elective cardiac surgery;
Have signed the informed consent form (ICF).
Disqualifiers
Patients undergoing emergency surgery;
Patients undergoing deep hypothermic circulatory arrest surgery;
Preoperative predicted mortality >3% according to European System for Cardiac Operative Risk Evaluation II (EuroSCORE II);
Patients undergoing off-pump coronary artery bypass grafting (off-pump CABG) surgery;
Trial design
Treatments tested in this trial
- Colchicine 0.5 MG
- Placebo
Treatment groups
Sponsors and collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead sponsor
First Affiliated Hospital of Zhejiang University
Collaborator
Jinan Central Hospital
Collaborator
The First People's Hospital of Changzhou
Collaborator
Xinhua hospital of ILi in Kazakhstan automomous district
Collaborator
First Affiliated Hospital of Harbin Medical University
Collaborator
Yangzhou University
Collaborator
Shandong Provincial Hospital
Collaborator
Huai'an First People's Hospital
Collaborator
The First Affilated Hospital of the Medical College, Shihezi University
Collaborator
Affiliated Hospital of Nantong University
Collaborator